Finance
Bharat Biotech’s CMD Krishna Ella announced on Saturday that the company’s intranasal Covid-19 vaccine iNCOVACC will be available on January 26.
The nasal vaccine, the first of its kind in India, had already been approved by the Central Drugs Standard Control Organization (CDSCO) earlier this month.
“Our nasal vaccine will be officially launched on Republic Day on January 26,” said Ella while participating in a session during the 8th edition of the India International Science Festival (IISF) that began at the Maulana Azad National Institute of Technology (MANIT), here on Saturday.
The session was titled ‘Face-to-Face with New Frontiers in Science’.
The company previously stated that the intranasal vaccine would be priced at Rs 325 per shot for government procurement and Rs 800 per shot for private vaccination centers.
According to the vaccine manufacturer, the nasal route has excellent vaccination potential due to the organized immune system of the nasal mucosa. Intranasal immunization with ChAd-SARS-CoV-2-S can elicit an immune response in the nose, which is the virus’s point of entry, protecting against disease, infection, and transmission.
The nasal vaccine can be taken after six months of the second dose.
Source:SE
